bekanamycin and arbekacin

bekanamycin has been researched along with arbekacin* in 1 studies

Other Studies

1 other study(ies) available for bekanamycin and arbekacin

Article	Year
Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus. The Journal of antimicrobial chemotherapy, 1995, Volume: 35, Issue:6 Arbekacin (1-N-((S)-4-amino-2-hydroxybutyryl)-3',4'-dideoxykanamycin B) was active against 54 strains of methicillin-resistant Staphylococcus aureus from 16 different countries, all of which were resistant to > or = 32 mg/L amikacin. MICs of arbekacin ranged from 1 to 16 mg/L, the MIC50 was 3.2 mg/L and the mode geometric mean MICs were 4 and 4.5 mg/L respectively. Topics: Aminoglycosides; Anti-Bacterial Agents; Dibekacin; Kanamycin; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus	1995

Article

Year

Activity of the semi-synthetic kanamycin B derivative, arbekacin against methicillin-resistant Staphylococcus aureus.

The Journal of antimicrobial chemotherapy, 1995, Volume: 35, Issue:6

Arbekacin (1-N-((S)-4-amino-2-hydroxybutyryl)-3',4'-dideoxykanamycin B) was active against 54 strains of methicillin-resistant Staphylococcus aureus from 16 different countries, all of which were resistant to > or = 32 mg/L amikacin. MICs of arbekacin ranged from 1 to 16 mg/L, the MIC50 was 3.2 mg/L and the mode geometric mean MICs were 4 and 4.5 mg/L respectively.

Topics: Aminoglycosides; Anti-Bacterial Agents; Dibekacin; Kanamycin; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus

1995